dihexa hgf c met synaptogenesis Activated HGF-c-Met Axis in Head and Neck Cancer 🧬 Incredible visualization of real-time

In clinical studies targeting obesity, particularly in the phase 3 trials based on the SURPASS program, tirzepatide demonstrated outstanding weight reduction benefits, with some patients achieving a weight loss of up to 22.5%

Suggested Use: Take 1 capsules daily or use as directed by your healthcare practitioner

Dec 29, 2025 Cagrilintide is a long-acting amylin receptor agonist that produces 10-12% body weight loss through mechanisms completely different from GLP-1s - dramatically slowing gastric emptying, suppressing appetite via brain amylin receptors, and reducing postprandial glucose

Analysis of body composition further demonstrated that Cagrilintide specifically reduced fat mass while preserving lean mass in WT mice

These timelines reflect typical clinical observations, not guaranteed outcomes